Report cover image

Catalyst Monitor: Q2 2026 Outlook

Publisher GlobalData
Published Mar 26, 2026
Length 92 Pages
SKU # GBDT21112476

Description

Catalyst Monitor: Q2 2026 Outlook

Summary

This report compiles published, predictive intelligence based on interviews with key opinion leaders (KOLs) on market-moving events that are expected to occur in Q2 2026.

GlobalData’s latest report, “Catalyst Monitor Q2 2026”, delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, top-line results, regulatory filings, PDUFA dates, and expected approvals. The report covers 15 significant catalyst events that are expected to occur in Q2 2026.

Some of the catalysts covered in the report, include approval decisions for Replimune’s vusolimogene oderparepvec in melanoma, Arvinas’s vepdegestrant in ER+/HER2-Negative Breast Cancer, and more.

Additionally, experts also discuss expectations about the ongoing clinical trials such as Regenxbio’s Phase III trial results in Duchenne muscular dystrophy and Boehringer Ingelheim’s Phase III trial results in obesity, and more.

The Catalyst Monitor report is published on a quarterly basis. The data presented in this report reflects the database as of 26 March.

Scope
  • The Q2 Catalyst Monitor report offers exclusive forward-looking insights on Phase II and Phase III results, regulatory drug approvals and more, based on exhaustive research and exclusive KOL interviews.
Reasons to Buy

This report will enable the user to answer the following questions -
  • Which biopharma companies are expecting major milestones such as FDA decisions or late-stage trial completions and results in Q2 2026?
  • Which upcoming regulatory catalysts that are expected in Q2 2026 are likely to be market-moving events?
  • How do the number of expected regulatory events like trial initiations and trial completions in Q2 2026 compare to the previous quarter?
  • Which are the top therapy areas for market-moving catalysts in Q2 2026 compared to the previous quarter?
  • Which companies have the highest numbers of upcoming catalysts expected in Q2 2026?
  • How do KOLs assess the US approval prospects of Replimune’s vusolimogene oderparepvec in melanoma, following BLA resubmission?
  • What are the expectations regarding Arvinas’s FDA approval for vepdegestrant in ER+/HER2-Negative Breast Cancer, and how will the therapy be integrated into the treatment landscape?

Table of Contents

92 Pages
About GlobalData
Quarterly Catalyst Comparisons
Catalyst Calendar
Catalysts
Appendix
List of Tables
Quarterly Catalyst Comparisons- Event Type
Quarterly Catalyst Comparisons- Therapy Area
Quarterly Catalyst Comparisons- Molecule Type
Quarterly Catalyst Company Breakdown
Catalyst Calendar

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us